Revenue
2019
2020
2021
2022
2023
2024
2025
2026
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.94B | $5.46B | $5.14B | $4.54B | $4.22B | $3.11B | $3.03B | $2.78B | $2.62B | $2.61B |
| Gross profit | $2.63B | $2.40B | $2.22B | $1.98B | $1.88B | $1.34B | $1.32B | $1.17B | $1.09B | $1.03B |
| Research & development | $112.9M | $107.6M | $103.7M | $98.5M | $86.7M | $66.3M | $65.5M | $63.0M | $60.8M | $59.4M |
| Operating expenses | $1.52B | $1.54B | $1.38B | $1.19B | $1.41B | $794.7M | $783.0M | $764.0M | $692.9M | $800.0M |
| Operating income | $1.10B | $866.6M | $836.1M | $791.1M | $477.8M | $548.4M | $537.0M | $411.0M | $399.9M | $226.2M |
| EBITDAderived | $1.59B | $1.34B | $1.40B | $1.34B | $1.03B | $767.6M | $734.3M | $636.9M | $578.2M | $414.3M |
| Net income | $782.3M | $614.6M | $378.2M | $107.0M | $243.9M | $397.4M | $407.7M | $303.7M | $290.9M | $110.0M |
| Basic EPSper diluted share | $7.97 | $6.24 | $3.83 | $1.07 | $2.50 | $4.66 | $4.81 | $3.59 | $3.42 | $1.29 |
| Diluted EPSper diluted share | $7.93 | $6.20 | $3.81 | $1.07 | $2.48 | $4.63 | $4.76 | $3.55 | $3.39 | $1.28 |
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 · 10b5-1 | Zangerle John AdamSr. VP, Gen Counsel, and Sec. | SellOrdinary Shares | 1.4K | $209.28 | $297.0K | 35.3K |
| Jun 5, 2026Form 4 · 10b5-1 | Carestio Daniel APresident and CEO | SellOrdinary Shares | 1.4K | $212.00 | $291.3K | 63.6K |
| Jun 4, 2026Form 4 · 10b5-1 | Carestio Daniel APresident and CEO | SellOrdinary Shares | 3.1K | $214.64 | $655.5K | 65.0K |
| Jun 2, 2026Form 4 | Breeden Richard CDirector | SellOrdinary Shares | 1.5K | $209.51 | $310.3K | 39.0K |
| Mar 5, 2026Form 4 | FELDMANN CYNTHIA LDirector | SellOrdinary Shares | 3.1K | $237.21 | $734.9K | 705 |